Merck & Co., Inc. (NYSE:MRK) Q4 2023 Earnings Call Transcript February 1, 2024
Merck & Co., Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
Operator: Thank you for standing by. Welcome to the Merck & Co. Q4 Sales and Earnings Conference Call. [Operator Instructions] This call is being recorded. If you have any objections, you may disconnect at this time. I would now like to turn the call over to Mr. Peter Dannenbaum, Vice President, Investor Relations. Sir, you may begin.
Peter Dannenbaum: Thank you, Ivy and good morning everyone. Welcome to Merck’s fourth quarter 2023 conference call. Speaking on today’s call will be Rob Davis, Chairman and Chief Executive Officer; Caroline Litchfield, Chief Financial Officer; and Dr. Dean Li, President of Merck Research Labs. Before we get started, I’d like to point out a few items. You will see that we have items in our GAAP results, such as acquisition-related charges, restructuring costs and certain other items. You should note that we have excluded these from our non-GAAP results and provide a reconciliation in our press release. I would like to remind you that some of the statements that we make today maybe considered forward-looking statements within the meaning of the Safe Harbor provision of the U.S. Private Securities Litigation Reform Act of 1995.
Such statements are made based on the current beliefs of Merck’s management and are subject to significant risks and uncertainties. If our underlying assumptions prove inaccurate or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Our SEC filings, including Item 1A and the 2022 10-K identify certain risk factors and cautionary statements that could cause the company’s actual results to differ materially from those projected in any of our forward-looking statements made this morning. Merck undertakes no obligation to publicly update any forward-looking statements. During today’s call, a slide presentation will accompany our speakers’ prepared remarks. These slides, along with the earnings release, today’s prepared remarks and our SEC filings, are all posted to the Investor Relations section of Merck’s website.
With that, I’d like to turn the call over to Rob.
Rob Davis: Thanks Peter. Good morning and thank you for joining today’s call. 2023 was another very strong year for Merck. I am extremely pleased by the progress we have made to develop and deliver transformative therapies and vaccines that will help save and improve lives around the world. We reached more than 500 million people with our medicines last year alone. Over half of which were through donations. We also made substantial investments in research and development in our ongoing effort to discover and bring forward to patients the next generation of impactful innovations, over $30 billion in total, including the cost of certain acquisitions and collaborations. As we move forward, I am confident that our strong momentum will continue, underpinned by the unwavering dedication of our talented global team.
We are realizing the benefits of our sustained focus on key strategic priorities. The excellence of our commercial and operational execution enables us to deliver tangible value in the short-term while we invest in new innovations and strengthen our pipeline for the long-term. In 2023, we advanced important clinical programs and augmented our pipeline with promising business development, such as the acquisition of Prometheus and our collaboration with Daiichi Sankyo. Guided by our science-led strategy, I am confident that the focused and disciplined business decisions we make and the actions we take will lead to sustainable benefits for the patients we serve and long-term growth and value for our shareholders. Turning to our results and initial outlook for 2024, we delivered excellent underlying growth in 2023, reflecting robust demand for our innovative portfolio.
I am pleased to share that we expect continued strong growth in 2024 driven by demand for our key products, which Caroline will speak to momentarily. Turning to the progress we are making in research, we are currently pursuing programs across a more diverse set of therapeutic areas with high unmet need and across more modalities than at any time in recent memory. This year, we will remain keenly focused on advancing our broad and diverse pipeline, which includes two launches that will address critical health needs and have blockbuster commercial opportunity. In cardiometabolic, we are very excited by the anticipated FDA action on our application for sotatercept in the United States, which we believe has the potential to transform the treatment journey for many patients suffering from pulmonary arterial hypertension.
Our commercial and manufacturing teams are fully prepared for the strong uptake we expect. Sotatercept is an important component of our growing cardiometabolic pipeline, which we believe has significant long-term potential. In vaccines, the FDA accepted for priority review our filing for V116. If approved, V116 would be the first vaccine specifically designed to address the majority of invasive pneumococcal disease in adults ages 65 and older. Based on its compelling profile, V116 has the potential to become an important new preventative option for adults and we believe it can achieve majority market share in this setting. We look forward to a potential approval in June. And in oncology, we continue to expand into additional tumor types in earlier stages of certain cancers as well as progress our increasingly broad pipeline of novel candidates.
We have achieved substantial diversification with a dramatically expanded set of late-stage programs, which Dean will speak to. I am confident that Merck is well positioned to provide important innovation to patients and sustain its leadership in oncology well into the future. I know Dean and his team are energized by our progress and are prepared to build on the success we have had in 2023 to further advance Merck’s pipeline and bring transformative innovation to patients this year and beyond. In summary, our science-led strategy, which keeps the patient at the center of everything we do, is delivering important advancements and helping us build a sustainable growth engine for our company. We have made considerable progress over the past year in advancing and expanding our pipeline, which has resulted in substantially increased long-term commercial opportunities.
We have taken meaningful steps to diversify and position ourselves for sustained leadership in oncology while also building one of our deepest and broadest pipelines across discovery and development in our recent history outside of oncology and notably in cardiometabolic and immunology. Further, we also expect to benefit from promising late-stage programs across our vaccines, neurosciences, HIV and animal health pipelines, a robust set of early phase programs and the potential to add exciting innovation through future science-led business development. As a result, we are increasingly confident that we are well positioned to drive patient impact and value creation this year and well into the next decade. I would again like to thank our global teams for their commitment to strong research, commercial and operational execution.
With a concerted focus on achieving continued excellence, I am very confident in our ability to deliver short and long-term stakeholder value. I look forward to providing future updates on our progress and impact. With that, I will turn the call over to Caroline.
Caroline Litchfield: Thank you, Rob. Good morning. 2023 was another impactful year for our company. We delivered strong revenue growth of 12%, excluding LAGEVRIO and foreign exchange. Growth was driven by robust performance across oncology, vaccines and animal health. We remain confident in our ability to continue to deliver strong results in the near-term while making disciplined investments in innovative science, which will drive long-term value for patients and shareholders. Now turning to our fourth quarter results. Total company revenues were $14.6 billion. Excluding the impact from LAGEVRIO and foreign exchange, the business delivered strong growth of 13%. The following revenue comments will be on an ex-exchange basis.
Our Human Health business sustained its momentum. Excluding LAGEVRIO, growth was 14% driven by Oncology and Vaccines. Sales in our Animal Health business increased 4% driven by companion animal products. Turning to the performance of our key brands. In Oncology, sales of KEYTRUDA grew 22% to $6.6 billion. Global growth was driven by increased uptake in earlier stage cancers, including triple-negative breast cancer and renal cell carcinoma, with particularly strong growth in international markets due to the more recent launches of these important indications. Growth was also driven by the strong global need of patients with metastatic disease. We continue to be encouraged by the positive impact our recent approvals are having on certain patients with earlier stage non-small cell lung cancer.
In the U.S., we have made considerable progress in helping to improve drug treatment rates and have further increased our leadership position in the adjuvant setting. We also received positive feedback from healthcare providers following the recent launch of KEYNOTE-A39 in advanced urothelial cancer. With this approval, KEYTRUDA in combination with PADCEV is now indicated for first-line advanced urothelial cancer patients regardless of cisplatin eligibility. Based on the outstanding clinical data, we believe this regimen has the potential to transform the standard of care for these patients. Alliance revenue from Lynparza and Lenvima grew 8% and 5% respectively. WELIREG sales grew 78% to $72 million driven by increased uptake in VHL-associated tumors.
We are excited by the opportunity to provide a new treatment option for certain patients with previously treated advanced renal cell carcinoma, following the recent approval based on the LITESPARK-005 study. Our Vaccines portfolio delivered excellent growth led by GARDASIL, which increased 27% to $1.9 billion, driven by global demand, particularly in China. In the U.S., GARDASIL sales benefited from CDC purchasing patterns. VAXNEUVANCE sales grew to $176 million driven by ongoing launches in Europe and continued uptake of the pediatric indication in the U.S. As a reminder, fourth quarter 2022 sales in the U.S. benefited from inventory stocking in preparation for the pediatric launch. In our hospital acute care portfolio, BRIDION sales declined 3%.
Increased market share among neuromuscular blockade reversal agents in the U.S. was more than offset by the impact of generic entrants in international markets, particularly in Europe. Our Animal Health business delivered another solid quarter, with sales increasing 4%. Companion animal sales grew 12% driven by the BRAVECTO line of products due to strong underlying demand and timing of purchases. Livestock sales were flat, reflecting favorable price actions offset by the timing of ruminant product purchases. I will now walk you through the remainder of our P&L and my comments will be on a non-GAAP basis. Gross margin was 77.2%, an increase of 1.5 percentage points largely due to favorable product mix, including a benefit from lower sales of LAGEVRIO.
Operating expenses increased to $11.6 billion, including a $5.5 billion one-time charge related to our collaboration with Daiichi Sankyo. Excluding this charge, operating expenses grew 8%, reflecting disciplined investment in support of our expansive early-and late-phase pipeline and key growth drivers. Other expense was $174 million. Our tax rate was approximately 114%, which reflects the impact of the charge related to Daiichi Sankyo. Excluding this charge, the underlying tax rate was 13.1%. Taken together, earnings per share were $0.03, which includes a $1.69 negative impact from the charge related to Daiichi Sankyo. Now turning to our 2024 non-GAAP guidance. We expect another year of strong growth driven by key marketed products and we will begin to benefit from the anticipated launches of impactful new products, such as sotatercept and V116.
We project revenue to be between $62.7 billion and $64.2 billion, representing growth of 4% to 7%. This growth includes a negative impact from foreign exchange of approximately 2% using mid-January rates. The headwind is primarily due to the devaluation of the Argentine peso, which we expect will largely be offset by inflation-related price increases, consistent with market practice. Our gross margin assumption is approximately 80.5%, which includes the benefit from reduced royalties paid on KEYTRUDA and GARDASIL. Operating expenses are assumed to be between $25.1 billion and $26.1 billion, which includes an approximate $650 million one-time charge related to the announced acquisition of Harpoon Therapeutics. As a reminder, our guidance does not assume additional significant potential business development transactions.
Other expense is expected to be approximately $200 million. We assume a full year tax rate between 14.5% and 15.5%. We assume approximately 2.54 billion shares outstanding. Taken together, we expect EPS of $8.44 to $8.59. This range includes an approximate $0.26 per share charge related to the planned acquisition of Harpoon Therapeutics, which is not tax-deductible and the negative impact from foreign exchange of approximately $0.25 using mid-January rates, including the impact from Argentina. Now turning to capital allocation, where our strategy remains unchanged. We will prioritize investments in our business to drive near and long-term growth. We are excited by the significant progress our team has made to advance and augment our innovative pipeline in 2023.
In 2024, we will increase this investment, including the initiation of more late-stage clinical trials across multiple novel candidates, each of which has significant potential to address important unmet medical needs. We remain committed to our dividend and plan to increase it over time. Business development remains a high priority. We maintain ample capacity given our strong investment-grade credit rating and cash flow to pursue additional science-driven, value-enhancing transactions going forward. We will continue to execute a modest level of share repurchases. To conclude, we enter 2024 with confidence in the outlook for our business in the near and long term. Global demand for our innovative medicines and vaccines remain strong, and we are excited about our expansive pipeline.
We are in a position of financial and operational strength as a direct result of our longstanding commitment to science in order to improve the lives of the patients we serve. Our continued investment in innovation and excellent execution will enable us to deliver value to patients, customers and shareholders well into the future. With that, I’d now like to turn the call over to Dean.
Dean Li: Thank you, Caroline. Good morning. Today, I will provide notable R&D updates since our last earnings call and a brief summary of 2023 accomplishments. Momentum in the pipeline remains strong. Progress is spanning both early- and late-phase programs across multiple therapeutic areas. Starting with Oncology, we are diversifying our portfolio and executing on our strategy, which is broadly based on three strategic pillars: immunooncology, precision molecular targeting and tissue targeting. In immunooncology, we remain committed to the development of KEYTRUDA and further transforming cancer care to address the needs of certain patients. In the fourth quarter, we received approvals from both the FDA and the European Commission in two gastrointestinal indications: one in combination with chemotherapy for the first line treatment of adults with locally advanced, unresectable or metastatic HER2-negative gastric or gastroesaphageal junction adenocarcinoma based on KEYNOTE-A59; and another in combination with gemcitabine and cisplatin for the treatment of patients with locally advanced, unresectable or metastatic biliary tract cancer based on KEYNOTE-966.
As we continue to harness the potential of KEYTRUDA, we have an increased focus on earlier stages of disease, where we believe timely, effective intervention may significantly improve patient outcomes. Last month, we announced FDA approval for KEYTRUDA in combination with chemo radiotherapy for the treatment of fecal Stage 3 through 4A cervical cancer based on the Phase 3 KEYNOTE-A18 trial. This is an important advancement and provides a new option that has potential to become the standard of care. To-date, with all the research conducted with checkpoint inhibitors, the only studies that have demonstrated statistically significant overall survival benefit in earlier stage cancers are KEYTRUDA-based regimens: KEYNOTE-671 as part of a neoadjuvant followed by post-surgery adjuvant treatment regimen for certain patients with resectable non-small cell lung cancer and KEYNOTE-564 as a post-surgery adjuvant treatment regimen for certain patients with renal cell carcinoma.
Since the approval of a KEYNOTE-671 in October, it is notable that the American Cancer Society released guidance recommending that certain individuals with significant smoking history undergo an annual low-dose CT scan. The guidance also expands the age range for lung cancer screening. We look forward to the opportunity to help impact patients and support the identification of more patients at risk. Additional data from KEYNOTE-564 demonstrating an overall survival benefit were presented at the ASCO GU conference last week. Detailed findings from KEYNOTE-123 evaluating KEYTRUDA for the adjuvant treatment of patients with localized, muscle-invasive and locally advanced, resectable urothelial carcinoma demonstrating a disease-free survival benefit versus observation were also presented at ASCO GU.
Also in the earlier-stage setting, along with our partner, Moderna, we announced 3-year recurrent-free survival and distant metastasis-free survival data for our individualized neoantigen therapy, V940, in combination with KEYTRUDA for the adjuvant treatment of Stage 3 and 4 melanoma following complete resection. We are encouraged by the durability of the responses observed and the potential for this regimen to impact patients earlier in their diagnosis. The Phase 3 trials in the adjuvant setting for certain patients with melanoma and non-small cell lung cancer are actively enrolling. Progress continues in precision oncology. The FDA approval for WELIREG, our HIF 2 alpha inhibitor for the treatment of adults with advanced RCC following a PD-1 or PD-L1 inhibitor and a VEGF-TKI, marks the first drug approved in a new therapeutic class for eligible patients with advanced renal cell carcinoma in nearly a decade and builds on the 2021 approval for the treatment of adults with certain von Hippel-Lindau disease-associated tumors.
Additional Phase 3 pneumococcal studies for WELIREG, in combination with KEYTRUDA and/or lenvatinib for the treatment of certain types of renal cell carcinoma in the advanced and adjuvant settings, are ongoing. Finally, moving to the tissue targeting space. Together with Astellas and Seagen, now Pfizer, we announced the FDA approval for KEYTRUDA in combination with Padcev, a Nectin-4-targeting ADC for the first-line treatment to patients with locally advanced or metastatic urothelial cancer based on results from KEYNOTE-A39. These results demonstrated a superior overall survival benefit versus gemcitabine plus cisplatin or carboplatin and extend our pioneering work in combining KEYTRUDA with chemotherapy as well as reinforcing the value of an ADC to enable targeted delivery of chemotherapy to the tumor tissue.
Following the announcement of our collaboration with Daiichi Sankyo in October, we are pleased to receive priority review from the FDA for MK-1022, or patritumab deruxtecan, our investigation of a fully humanized anti-HER3 ADC for patients with advanced EGFR-mutated non-small cell lung cancer previously treated with two or more systemic therapies. The agency has set a target action date of June 26. Through our agreements with Kelun and Daiichi Sankyo as well as our own discovery programs, we have established a robust pipeline of tissue-targeting ADCs. And the recently announced acquisition of Harpoon Therapeutics provides the opportunity to help complement and strengthen our approach by providing a portfolio of novel T cell engagers, the most significant of which is HPN-328, an investigational delta-like ligand 3 targeting T cell engager being evaluated in small cell lung cancer and neuroendocrine tumors.
Our strong diverse portfolio of immuno-oncology precision molecular and tissue-targeting agents positions us well to have a profound impact on even more patients long into the future. Next to our Vaccine pipeline. We are making notable advancements with our population-specific vaccine program for pneumococcal disease. The FDA has accepted for priority review the new biologics license application for V116, our 21-valent pneumococcal conjugate vaccine, specifically designed for adults supported by results from multiple Phase 3 clinical trials evaluating V116 in both pneumococcal vaccine-naive and vaccine-experienced adult patient population. Results from STRIDE-3 trial were presented at the World Vaccine Congress West Coast in November and additional data from STRIDE-3 as well as STRIDE studies 4, 5 and 6 will be presented at the International Society of Pneumonia and Pneumococcal Disease Congress in March.
If approved, as Rob noted, V116 would be the first new pneumococcal-conjugate vaccine specifically designed to address the serotypes responsible for approximately 83% of invasive pneumococcal disease in about 65 years of age and older, according to CDC data from 2018 to 2021. Importantly, V116 includes eight unique serotypes, which account for 30% of disease according to the same CDC data. These serotypes are not covered by currently licensed pneumococcal vaccine options. The FDA has set a target action date of June 17. Turning to programs in the cardiometabolic disease pipeline. We are eager to bring sotatercept to patients as an important treatment option for pulmonary arterial hypertension. The FDA has set a target action date of March 26.
Beyond data from the STELLAR trial, we have the Phase 3 ZENITH and HYPERION studies, which are evaluating sotatercept in patients with more advanced disease and those earlier on their disease journey. In addition, the Phase 2 CADENCE trial will evaluate WHO Group 2 pulmonary hypertension focused on a type of blood clot disease. As we close out 2023, it is important to highlight our significant progress and execution across therapeutic areas and modalities as well as multiple business development transactions. In the year, we have more than 25 regulatory approvals in major markets. We also initiated over 20 Phase 3 studies across multiple new classes of assets, including in on oncology with bomedemstat, our LSD1 inhibitor in essential thrombocythemia; nemtabrutinib, our BTK inhibitor in first-line chronic lymphocytic leukemia of small lymphocytic lymphoma; MK-2870, our TROP2 ADC in collaboration with Kelun in non-small cell lung cancer and endometrial carcinoma; MK-5684, our CYP11A1 inhibitor in collaboration with Orion in metastatic castrate-resistant prostate cancer; and V940 in collaboration with Moderna for the adjuvant treatment of certain types of melanoma and non-small cell lung cancer; also in immunology, with tulisokibart in ulcerative colitis; finally, in cardiometabolic disease with multiple trials for MK-0616 in hypercholesterolemia.
As a result of the increasing depth and breadth of our pipeline, we are planning to initiate an even greater number of Phase 3 trials in 2024. Considerable credit goes to my colleagues across the organization for their hard work and unwavering dedication. We are executing on our science-led strategy and look forward to providing further updates on our progress throughout the year. And now I will turn the call back to Peter.
Peter Dannenbaum: Thank you, Dean. Ivy, we’re now ready to take questions. [Operator Instructions] Thank you.
See also 25 Largest Banks in the US by Total Deposits and 24 Countries Where You Can Retire on Just Social Security in 2024.
Q&A Session
Follow Merck Sharp & Dohme Corp. (NYSE:MRK)
Follow Merck Sharp & Dohme Corp. (NYSE:MRK)
Operator: [Operator Instructions] Our first question will come from the line of Umer Raffat from Evercore ISI. Please go ahead.
Umer Raffat: Hi, guys. Thanks for taking my questions. I know there is a trial due for you guys later this year, KEYFORM-007 trial. That’s the LAG-3 with pembrolizumab in colorectal cancer. Just curious how you’re thinking about the risk profile and the odds of success heading into that and if there is been any interim OS analysis. Thank you very much.
Dean Li: I’ll take this. Umer, thank you very much for that question. I mean just to recognize that in MSI high, we have a strong presence with pembro there. The larger group in CRC or colorectal cancer is in the MSS population. At this point, there is not really been any checkpoint inhibitor that’s shown dramatic impact in MSS CRC. So our interest in driving pembro plus LAG-3 in that is to demonstrate that a checkpoint inhibitor could have a meaningful impact in MSS CRC. If we should get a positive signal in that, clearly, we would use that as a beachhead to expand and extend the role of checkpoint inhibitors in MSS CRC, which is a place that requires a lot of more innovation. In terms of specific interim analysis on this, we generally try to keep that when there is data that’s worth sharing, that’s when we share it. Thanks.
Rob Davis: Just real quick, just quick microphone check. Can you hear us?
Operator: No, we can hear you.
Rob Davis: You can? Okay, we were showing we are muted. Sorry.
Operator: No, you are fine. We can hear you loud and clear.
Rob Davis: Alright. Good.
Peter Dannenbaum: Next questions please, Ivy?
Operator: Next, we will go to the line of Trung Huynh from UBS. Please go ahead.
Trung Huynh: Good morning, guys. Thanks for taking my question. So for sotatercept, we noticed the HYPERION study primary completion date has now moved to August 26. It was November 29 on clinicaltrials.gov. That’s 3 years earlier. Just – could you just let us know the reason for that change? And if I could sneak one in. Just is there a place to transition sotatercept from inpatient clinic administration to self-administration? Thanks very much.
Dean Li: So let me take the first question. So there is a series of trials and relationships with sotatercept. So the March date that we talk about is for a potential decision by the FDA for approval based on the STELLAR trial. And we think in the second half of 2024, we may be in a position in relationship to the EU. We have other trials, as you point out, especially Phase 3 trials, and they are ZENITH and they are HYPERION. Those two are based on events. So it’s a tracking of events that sort of define when those happen. So ZENITH, I think, is now like September 2025 and HYPERION, August 2026. So that’s just been event-driven. In relationship to how best to treat patients, well we’re in conversations with the FDA in relationship to where is the best place for patients to be treated. But I’ll just highlight that we have an image of an auto injector moving very fast through our pipeline. So that might give you a sense of where we think this may end up.
Peter Dannenbaum: Great. Thank you. Next question please Ivy.
Operator: Next, we will go to the line of Daina Graybosch from Leerink Partners. Please go ahead.
Daina Graybosch: Hi, thank you for the question. I have one on Oncology for one of the new assets going into Phase 3, the Orion MK-5684. I wonder if you could talk more about that asset. And what gives you confidence that it will demonstrate broad benefit in prostate cancer, in addition to the patients with the AR-LBD mutations? And can you confirm the stat design of the two Omaha studies will prioritize a hierarchy to statistically look at the mutation segment first?
Dean Li: Yes. So just so that everyone is looking at this asset in the same way, there have been critical medicines that ablate androgen field growth in prostate cancer. And the interest in the SIP is it’s very high upstream, and we think that it could be an important contribution. Clearly, we’re in – as you point out, we’re interested both broadly, but especially in the specific mutation patients. And so we will be advancing those trials to look at that subpopulation as well as more broad populations. In terms of the statistical sort of analysis in that, that’s something that I think probably would be best sort of discussed with our clinical teams at a different time.
Peter Dannenbaum: Thank you, Daina. Next question please.
Operator: Next, we will go to Carter Gould from Barclays. Please go ahead.
Carter Gould: Thank you very much for taking the question. Good morning. Maybe following up on the commentary on V116. You talked about a potential to reach a majority market share. What does that sort of imply around the potential ACIP recommendation or the potential for a catch-up opportunity in the adult segment?
Dean Li: Yes. So I’ll just – so again, we’re talking about V116. We’re talking about FDA potential action in June 2024, followed by ACIP, followed by MMWR. I think it’s in March that we’re going to be presenting STRIDE-3 and 6, and I think the data will be out there. And as you’ll see in that, between STRIDE-3 and throughout STRIDE-3 all the way to 6, you’ll see data in relationship to vaccination of those who are naive versus previously vaccinated. And you will see data in the patient population – or the population that 65, but also in the 50-plus as well. As that data is digested, both by the FDA, but probably very importantly, by the ACIP, I think those data will guide how the ACIP makes their decision.
Peter Dannenbaum: Great. Anything else? Okay, next question please, Ivy?
Operator: Next, we will go to the line of Evan Seigerman from BMO Capital Markets. Please go ahead.
Evan Seigerman: Hi, guys. Thank you so much for taking my questions. I was wondering if you could expand on some of the nuances of your guidance. Specifically, do you include meaningful revenues from sotatercept or V116? I’m assuming they are for approval at some point this year.
Caroline Litchfield: Thank you for the question, Evan. This is Caroline. As we’ve guided for 2024, we’re very confident in the underlying momentum in our business across Oncology, across Vaccines, across Animal Health. We also are very excited about the potential launches for sotatercept and V116. For sotatercept, given the significant clinical data we have and the understanding that there are many patients that have already been identified who can benefit for sotatercept on top of the treatments they have, we are expecting a strong launch. For V116, as Dean just outlined, we will wait for the FDA approval, the ACIP recommendation. We will then expect MMWR to publish, and therefore, expect to have impact with V116 coming towards the end of this year.
Peter Dannenbaum: Great. Thanks, Evan. Next question please, Ivy?
Operator: Next, we will go to the line of Terence Flynn from Morgan Stanley. Please go ahead.
Terence Flynn: Great. Thanks so much for taking the question. A competitor recently reported some disappointing data with their TROP2 ADC and later line lung. I recognize these TROP2s are all different given the technology, the linkers. But does this impact at all your development strategy for your TROP2 in lung or perhaps increase the need for a biomarker strategy here? Thank you.
Dean Li: Yes. This is Dean. Thanks for that question. So I’ll just step back, and I think I’ve said this previously, especially in lung, it’s very important to understand what the standard of care is and that one would have to beat it in a significant way. And the standard of care, in our minds, in the late stage, is roughly KEYNOTE-189. And now in the earlier stage, it’s clearly in KEYNOTE-671 both with clear OS data. What we have said previously is that we are unclear that any one ADC can have as broad of an impact as KEYNOTE-189 or 671 and that in order for ADC to have a substantial advantage in those patient populations, one may need to focus on a biomarker-selected patient population. And so the data that we saw does not change our way of thinking.